The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women
- 26 April 2004
- Vol. 100 (11) , 2308-2316
- https://doi.org/10.1002/cncr.20271
Abstract
BACKGROUND: Statin use has increased dramatically in the U.S. in the past decade. Animal and mechanistic studies suggested that statins may have an inhibitory effect on cancer proliferation, including breast carcinoma. However, statins have been found to be carcinogenic in rodents and one clinical trial found an excess of breast carcinoma cases in the treatment group.METHODS: The current study assessed whether the use of statins altered the risk of breast carcinoma in older women. The population‐based, case–control study comprised female residents from three western Washington State counties. Cases included 975 women identified from the Cancer Surveillance System who were diagnosed with primary invasive breast carcinoma between 1997–1999, whose names appeared on a list of Social Security recipients provided by the Centers for Medicare and Medicaid Services. The cases were ages 65–79 years at the time of diagnosis. The comparison group was comprised of 1007 women without breast carcinoma who were randomly selected from the same list of Social Security recipients. Information pertaining to statin use, medical history, and health behaviors was ascertained through an in‐person interview.RESULTS: Compared with nonusers, women who were currently using statins or had ever used statins were not found to be at an increased risk for breast carcinoma (odds ratios [OR] = 0.9; 95% confidence interval [95% CI], 0.7–1.2). There was some indication that long‐term statin use (> 5 years) was related to a slight decrease in breast carcinoma risk (OR = 0.7; 95% CI, 0.4–1.0).CONCLUSIONS: The results of the current study provided some degree of reassurance to the increasing numbers of women using statins that such use is not associated with an increased risk of breast carcinoma. Although the data gave some support to a reduced risk of breast carcinoma among long‐term users of statins, further research is needed to confirm this association. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Lovastatin Induced Control of Blast Cell Growth in an Elderly Patient with Acute Myeloblastic LeukemiaLeukemia & Lymphoma, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- A Comparison of the Effect of the 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors Simvastatin, Lovastatin and Pravastatin on Leukaemic and Normal Bone Marrow ProgenitorsLeukemia & Lymphoma, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Lovastatin Inhibits Proliferation and Differentiation and Causes Apoptosis in Lipopolysaccharide-Stimulated Murine B CellsBiochemical and Biophysical Research Communications, 1995
- Lovastatin Induces Growth Inhibition and Apoptosis in Human Malignant Glioma CellsBiochemical and Biophysical Research Communications, 1994
- Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian womenCancer Causes & Control, 1994
- Serum cholesterol and risk of cancer in a cohort of 39,000 men and womenJournal of Clinical Epidemiology, 1988